RA CAPITAL MANAGEMENT, L.P.'s Net Worth
$2.54 Billion
Who is RA CAPITAL MANAGEMENT, L.P.?
RA CAPITAL MANAGEMENT, L.P. has an estimated net worth of $2.54 Billion. This is based on reported shares across multiple companies, which include AN2 Therapeutics, Inc., RHYTHM PHARMACEUTICALS, INC., Vaxcyte, Inc., Dicerna Pharmaceuticals Inc, Eidos Therapeutics, Inc., iTeos Therapeutics, Inc., Mineralys Therapeutics, Inc., Cytek Biosciences, Inc., PMV Pharmaceuticals, Inc., Nkarta, Inc., DICE Therapeutics, Inc., SANGAMO BIOSCIENCES INC, Icosavax, Inc., Tyra Biosciences, Inc., MIRAGEN THERAPEUTICS, INC., Inhibrx, Inc., RxSight, Inc., Phathom Pharmaceuticals, Inc., Dyne Therapeutics, Inc., TG THERAPEUTICS, INC., Aclaris Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Eliem Therapeutics, Inc., KalVista Pharmaceuticals, Inc., Vor Biopharma Inc., Verastem, Inc., Janux Therapeutics, Inc., Aerovate Therapeutics, Inc., Forma Therapeutics Holdings, Inc., Therapeutics Acquisition Corp., G1 Therapeutics, Inc., ARVINAS INC., Synthorx, Inc., CURIS INC, Acumen Pharmaceuticals, Inc., 89bio, Inc., Solid Biosciences Inc., Inozyme Pharma, Inc., Pandion Therapeutics, Inc., Iterum Therapeutics plc, Kala Pharmaceuticals, Inc., Orchard Therapeutics plc, scPharmaceuticals Inc., Satsuma Pharmaceuticals, Inc., Akouos, Inc., Cardiff Oncology, Inc., Wave Life Sciences Ltd., Werewolf Therapeutics, Inc., Enliven Therapeutics, Inc., Ra Pharmaceuticals, Inc., Fulcrum Therapeutics, Inc., ACHILLION PHARMACEUTICALS INC, ARS Pharmaceuticals, Inc., PepGen Inc., Black Diamond Therapeutics, Inc., DERMA SCIENCES, INC., SEQUENOM INC, BIOSPECIFICS TECHNOLOGIES CORP, Acrivon Therapeutics, Inc., ARADIGM CORP, and LIPID SCIENCES INC/.
SEC CIK
RA CAPITAL MANAGEMENT, L.P.'s CIK is 0001346824
Past Insider Trading and Trends
2008 was RA CAPITAL MANAGEMENT, L.P.'s most active year for acquiring shares with 337 total transactions. RA CAPITAL MANAGEMENT, L.P.'s most active month to acquire stocks was the month of May. 2014 was RA CAPITAL MANAGEMENT, L.P.'s most active year for disposing of shares, totalling 166 transactions. RA CAPITAL MANAGEMENT, L.P.'s most active month to dispose stocks was the month of August. 2020 saw RA CAPITAL MANAGEMENT, L.P. paying a total of $343,239,212.72 for 42,610,963 shares, this is the most they've acquired in one year. In 2020 RA CAPITAL MANAGEMENT, L.P. cashed out on 129,210,338 shares for a total of $1,603,221,525.90, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
AN2 Therapeutics, Inc. (ANTX) Snapshot price: $20.04
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +52.94% | 1.78M |
$9.00 | $16,000,002.00 | 5.14M |
Aug 18
| |||
Form 4
| +0.03% | 1.91K |
$7.74 | $14,330.32 | 7.55M |
Aug 3 - Aug 4
| |||
Form 4
| +0.62% | 23.22K |
$7.78 | $180,674.69 | 3.77M |
Jul 26 - Jul 27
| |||
Form 4
| +0.01% | 302 |
$7.99 | $2,412.98 | 3.75M |
Jun 21
| |||
Form 4
| +2.22% | 81.42K |
$7.95 | $647,401.86 | 3.75M |
Jun 13 - Jun 14
| |||
Form 4
|
∞
| 3.67M |
$15.00 |
—
| 3.67M |
Mar 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
RHYTHM PHARMACEUTICALS, INC. (RYTM) Snapshot price: $47.91
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -5.19% | -238.54K |
$29.47 | -$7,029,652.62 | 4.36M |
Dec 2 - Dec 3
| |||
Form 4
| -2.50% | -131.58K |
$22.06 | -$2,902,517.12 | 5.14M |
Jun 30 - Jul 2
| |||
Form 4
| -2.77% | -150.32K |
$23.05 | -$3,465,614.60 | 5.27M |
Jun 25 - Jun 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Vaxcyte, Inc. (PCVX) Snapshot price: $74
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -5.05% | -266.26K |
$50.78 | -$13,521,592.46 | 5M |
Oct 7 - Oct 8
| |||
Form 4
| -3.94% | -221.33K |
$49.81 | -$11,245,562.88 | 5.39M |
Sep 29 - Oct 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Dicerna Pharmaceuticals Inc No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +108.93% | 2.65M |
—
|
—
| 5.07M |
Dec 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 16
| |||
Form 4
|
∞
| 2.43M |
$15.00 |
—
| 2.43M |
Feb 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Eidos Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 2.16M |
$17.00 |
—
| 2.16M |
Jun 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |